Under the optimized conditions, the method was successfully validated following EMA guidelines and its clinical applicability was confirmed in a multicenter, randomized, double-blind, placebo-controlled, phase II study to monitor ambroxol levels in the plasma and CSF of GBA1-PD subjects. Here, GBA1 is linked to Parkinson disease.